The Levels of H11/HspB8 DNA Methylation in Human Melanoma Tissues and Xenografts Are a Critical Molecular Marker for 5-Aza-2′-Deoxycytidine Therapy

被引：23

作者：

Smith, Cynthia C. ^{[1
]}

Li, Baiquan ^{[1
]}

Liu, Juan ^{[1
]}

Lee, Kie-Sok ^{[1
]}

Aurelian, Laure ^{[1
]}

机构：

[1] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA

来源：

CANCER INVESTIGATION | 2011年 / 29卷 / 06期

基金：

美国国家卫生研究院;

关键词：

Gene expression; Molecular biology; Cutaneous melanoma; Therapy; Prognosis and response predictions; HEAT-SHOCK-PROTEIN; MALIGNANT-MELANOMA; BETA-CATENIN; H11; KINASE; CYCLIN-E; METHYLTRANSFERASE PROMOTER; TUMOR-SUPPRESSOR; TP53; MUTATIONS; CELL-GROWTH; APOPTOSIS;

D O I：

10.3109/07357907.2011.584588

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

H11/HspB8 is a functionally distinct small heat shock protein. It causes growth arrest in melanocytes, associated with the inhibition of Cyclin E/Cdk2 and beta-catenin phosphorylation at the transcriptional activity site Ser(552) and is silenced through DNA methylation in 27/35 (77%) melanoma tissues/early cultures. 5-Aza-2 '-deoxycytidine (Aza-C) induces melanoma cell death correlated with the levels of H11/HspB8 DNA methylation (p < .001). In line with low/moderate H11/HspB8 methylation, PI3-K inhibition increases Aza-C-induced cell death. Aza-C inhibits the growth of melanoma xenografts related to the levels of H11/HspB8 methylation, and a nonmethylated/non-TAK1 binding H11/HspB8 mutant confers Aza-C resistance. H11/HspB8 is a potential molecular marker for demethylation therapies.

引用

页码：383 / 395

页数：13

共 58 条

[11] MICE LACKING P21(C/P1/WAF1) UNDERGO NORMAL DEVELOPMENT, BUT ARE DEFECTIVE IN G1 CHECKPOINT CONTROL [J].

DENG, CX ;

ZHANG, PM ;

HARPER, JW ;

ELLEDGE, SJ ;

LEDER, P .

CELL, 1995, 82 (04) :675-684

[12] H11 kinase prevents myocardial infarction by preemptive preconditioning of the heart [J].

Depre, C ;

Wang, L ;

Sui, XZ ;

Qiu, HY ;

Hong, C ;

Hedhli, N ;

Ginion, A ;

Shah, A ;

Pelat, M ;

Bertrand, L ;

Wagner, T ;

Gaussin, V ;

Vatner, SF .

CIRCULATION RESEARCH, 2006, 98 (02) :280-288

[13] H11 kinase is a novel mediator of myocardial hypertrophy in vivo [J].

Depre, C ;

Hase, M ;

Gaussin, V ;

Zajac, A ;

Wang, L ;

Hittinger, L ;

Ghaleh, B ;

Yu, XZ ;

Kudej, RK ;

Wagner, T ;

Sadoshima, J ;

Vatner, SF .

CIRCULATION RESEARCH, 2002, 91 (11) :1007-1014

[14]

Dhawan P, 2002, CANCER RES, V62, P7335

[15] Frequent p16-independent inactivation of p14ARF in human melanoma [J].

Freedberg, Daniel E. ;

Rigas, Sushila H. ;

Russak, Julie ;

Gai, Weiming ;

Kaplow, Margarita ;

Osman, Iman ;

Turner, Faye ;

Randerson-Moor, Juliette A. ;

Houghton, Alan ;

Busam, Klaus ;

Bishop, D. Timothy ;

Bastian, Boris C. ;

Newton-Bishop, Julia A. ;

Polsky, David .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (11) :784-795

[16] Promoter methylation profiling of 30 genes in human malignant melanoma [J].

Furuta, J ;

Umebayashi, Y ;

Miyamoto, K ;

Kikuchi, K ;

Otsuka, F ;

Sugimura, T ;

Ushijima, T .

CANCER SCIENCE, 2004, 95 (12) :962-968

[17] Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies [J].

Gallagher, WM ;

Bergin, OE ;

Rafferty, M ;

Kelly, ZD ;

Nolan, IM ;

Fox, EJP ;

Culhane, AC ;

McArdle, L ;

Fraga, MF ;

Hughes, L ;

Currid, CA ;

O'Mahony, F ;

Byrne, A ;

Murphy, AA ;

Moss, C ;

McDonnell, S ;

Stallings, RL ;

Plumb, JA ;

Esteller, M ;

Brown, R ;

Dervan, PA ;

Easty, DJ .

CARCINOGENESIS, 2005, 26 (11) :1856-1867

[18] TP53 mutations in familial breast cancer: Functional aspects [J].

Gasco, M ;

Yulug, IG ;

Crook, T .

HUMAN MUTATION, 2003, 21 (03) :301-306

[19] 2010 TNM Staging System for Cutaneous MelanomaaEuro¦and Beyond [J].

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Balch, Charles M. .

ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) :1475-1477

[20]

Ghosh Papia, 2009, Expert Rev Dermatol, V4, P131, DOI 10.1586/edm.09.2

← 1 2 3 4 5 6 →